| Literature DB >> 28446173 |
Xiaojin Sun1, T T Samba2, Jianyi Yao3, Wenwu Yin4, Lin Xiao5, Fuqiang Liu6, Xiaoqiang Liu7, Jikun Zhou8, Zengqiang Kou9, Hongwei Fan10, Hao Zhang11, Aqnes Williams2, Paul M Lansana2, Zundong Yin12.
Abstract
BACKGROUND: Since March 2014, the Ebola Virus Disease (EVD) outbreak in West Africa disrupted health care systems - especially in Guinea, Liberia and Sierra Leone - with a consequential stress on the area's routine immunization programs. To address perceived decreased vaccination coverage, Sierra Leone conducted a catch-up vaccination campaign during 24-27 April 2015. We conducted a vaccination coverage survey and report coverage estimates surrounding the time of the EVD outbreak and the catch-up campaign.Entities:
Keywords: Ebola virus disease; Field survey; Vaccination coverage
Mesh:
Substances:
Year: 2017 PMID: 28446173 PMCID: PMC5406892 DOI: 10.1186/s12889-017-4242-7
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Fig. 1Location of the three villages in Western Area Rural District, Sierra Leone
Fig. 2The three time points for vaccination coverage analysis and the epidemiology curve of EVD in Sierra Leone
Number of children over 9 months and 14 weeks old in the 3 study phases (before the EVD outbreak, during the EVD outbreak, and after the catch-up campaign)
| Ages | Items | Phase 1 (Before Aug1, 2014) | Phase 2 (Aug 2, 2014 – Apr 1, 2015) | Phase 3 (Aug 2, 2014 – May 1, 2015) |
|---|---|---|---|---|
| ≥9 M | DoBa covered | May 1, 2011- Oct 31, 2013 | Nov 1, 2013- Jul 1, 2014 | Nov 1, 2013- Aug 1, 2014 |
| No. of Children | 94 | 35 | 37 | |
| ≥14 W | DoBa covered | May 1, 2011- Apr 25, 2014 | Apr 26, 2014- Dec 22, 2014 | Apr 26, 2014- Jan 22, 2015 |
| No. of Children | 119 | 30 | 32 |
aNote: DoB = Date of birth
Age-eligible MV and Pentavalent3 coverage and changes by phases (before the EVD outbreak, during the EVD outbreak, and following the catch-up campaign)
| Phase 1 | Phase 2 | Changes (Phase 2–1) (95% CI) | Phase 3 | Changes (Phase 3–2) (95% CI) | |
|---|---|---|---|---|---|
| No. of vaccinated/ No. of investigated (Coverage 95% CI) | No. of vaccinated/ No. of investigated (Coverage 95% CI) | No. of vaccinated/ No. of investigated (Coverage 95% CI) | |||
| MV | |||||
| Jui | 32/37 (86.5, 75.5–97.5) | 8/13 (61.5, 35.1–88.0) | −25.0 (−50.2, 0.3) | 8/13 (61.5, 35.1–88.0) | 0.0 (−37.4, 37.4) |
| Grafton | 15/28 (53.6, 35.1–72.0) | 1/9 (11.1, 0–31.6) | −42.5 (−79.7, −5.3) | 4/10 (40.0, 9.6–70.4) | 28.9 (−10.8, 68.5) |
| Kossoh town | 20/29 (69.0, 52.1–85.8) | 7/13 (53.9, 26.8–81.0) | −15.1 (−46.5, −16.2) | 9/14 (64.3, 39.2–89.4) | 10.4 (−26.7, 47.5) |
| Subtotal | 67/94 (71.3, 62.1–80.4) | 16/35 (45.7, 29.2–62.2) | −25.6 (−44.2, −7.0) | 21/37 (56.8, 40.8–72.7) | 11.1 (−12.1, 34.1) |
| Pentavalent3 | |||||
| Jui | 39/45 (86.7, 76.7–96.6) | 6/9 (66.7, 35.9–97.5) | −20.0 (−46.7, 6.7) | 7/10 (70.0, 41.6–98.4) | 3.3 (−38.5, 45.2) |
| Grafton | 22/35 (62.9, 46.9–78.9) | 1/10 (10.0, 0–28.6) | −52.9 (−88.0, −17.7) | 3/10 (30.0, 1.6–58.4) | 20.0 (−15.1, 55.1) |
| Kossoh town | 34/39 (87.2, 76.7–97.7) | 5/11 (45.5, 16.0–74.9) | −41.7 (−69.4, −14.0) | 8/12 (66.7, 40.0–93.3) | 21.2 (−19.3, 61.8) |
| Subtotal | 95/119 (79.8, 72.6–87.0) | 12/30 (40.0, 22.5–57.5) | −39.8 (−57.8, −21.8) | 18/32 (56.3, 39.1–73.4) | 16.3 (−8.6, 41.1) |